Aclaris Therapeutics, Inc.
NASDAQ:ACRSBiotechnology
+$0.03 today
- Market cap
- $555.14M
- Beta
- 0.80
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$0.54
Volume 2.94M
Average 1.40M
ACRS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Aclaris Therapeutics, Inc.NASDAQ: ACRS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $15.66M rose 35.2% year over year, behind the +60.6% change in trailing-twelve-month research & development. Sequentially, it fell 5.6% from the prior quarter. Over 3 fiscal years it compounded at -12.2% a year.
Context
- Research & development amounted to 672.7% of revenue in FY2025, up 493.3 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +35.2% toward the trailing-twelve-month pace of +60.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 52.65M USD
- Year-over-year change
- +56.7%
- 4-year CAGR
- +4.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.65M | +56.7% |
| FY2024 | 2024-12-31 | 33.59M | -65.9% |
| FY2023 | 2023-12-31 | 98.38M | +26.4% |
| FY2022 | 2022-12-31 | 77.81M | +77.6% |
| FY2021 | 2021-12-31 | 43.81M | — |
Research & Development vs competitors
How ACRS compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +60.6% is the 2nd highest of 10, against a peer median of -8.4%.
- Research & development amounts to 677.9% of revenue for ACRS, versus a peer median of 4348.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $346.63M USD | -8.7% | +56.3% | 4685.4% |
| LTM Mar 2026 | $220.82M USD | +62.1% | +69.0% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $139.61M USD | -8.4% | — | — |
| LTM Mar 2026 | $128.65M USD | -23.4% | +15.3% | 55.4% | |
| LTM Mar 2026 | $86.08M USD | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $56.72M USD | +60.6% | -12.2% | 677.9% | |
| FY2025 | $54.15M USD | +59.9% | — | 4011.3% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €39.31M EUR | +49.4% | — | — |
| LTM Mar 2026 | €22.87M EUR | -34.8% | -11.8% | 77989.1% | |
| LTM Mar 2026 | $20.65M USD | -58.3% | -18.4% | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ACRS) | — | -8.4% | +10.0% | 4348.4% | |
Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.76M | 29.75M | 31.25M | 18.72M | 7.83M |
| Cost of Revenue | 4.71M | 11.96M | 18.08M | 2.79M | 2.09M |
| Gross Profit | 2.05M | 17.79M | 13.17M | 15.93M | 5.74M |
| Gross Margin | 30.3% | 59.8% | 42.1% | 85.1% | 73.3% |
| Research & Development | 43.81M | 77.81M | 98.38M | 33.59M | 52.65M |
| Selling, General & Admin | 23.62M | 25.13M | 31.1M | 22.2M | 21.97M |
| Operating Expenses | 91.77M | 107.65M | 110.53M | 157.86M | 82.11M |
| Depreciation & Amortization | 923K | 797K | 863K | 807K | 454K |
| EBITDA | (64.46M) | (84.36M) | (115.45M) | (51.72M) | (64.47M) |
| EBITDA Margin | -953.4% | -283.5% | -369.5% | -276.3% | -823.8% |
| Operating Income | (89.72M) | (89.85M) | (97.36M) | (141.93M) | (76.38M) |
| Operating Margin | -1327.1% | -302.0% | -311.6% | -758.2% | -975.9% |
| Interest Income | 0 | 0 | 0 | 7.95M | 7.64M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.14M) | 2.95M | 8.51M | 9.87M | 11.45M |
| Income Before Tax | (90.87M) | (86.91M) | (88.85M) | (132.07M) | (64.92M) |
| Pre-Tax Margin | -1344.0% | -292.1% | -284.3% | -705.5% | -829.6% |
| Income Tax Expense | 0 | 0 | (367K) | 0 | 0 |
| Net Income | (90.87M) | (86.91M) | (88.48M) | (132.07M) | (64.92M) |
| Net Margin | -1344.0% | -292.1% | -283.1% | -705.5% | -829.6% |
| EPS (Basic) | (1.60) | (1.33) | (1.27) | (1.71) | (0.53) |
| EPS (Diluted) | (1.60) | (1.33) | (1.27) | (1.71) | (0.53) |
| Weighted Avg Shares | 56.73M | 65.21M | 69.81M | 77.3M | 122.66M |
| Weighted Avg Shares (Diluted) | 56.73M | 65.21M | 69.81M | 77.3M | 122.66M |
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.